浏览全部资源
扫码关注微信
中国中医科学院 中药研究所 北京 100700
王芳,在读硕士,从事中药药理与毒理研究,E-mail:cikeywang@126.com
赵雍,硕士生导师,研究员,从事中药药理与毒理研究,Tel:010-84252805-2203,E-mail:yzhao@icmm.ac.cn; *
梁爱华,博士生导师,研究员,从事中药药理与毒理研究,Tel:010-84252805-2207,E-mail:ahliang@icmm.ac.cn
收稿日期:2023-02-06,
网络出版日期:2023-04-07,
纸质出版日期:2023-07-05
移动端阅览
王芳,李春英,易艳等.马兜铃水提物在大鼠体内代谢产物的定性分析[J].中国实验方剂学杂志,2023,29(13):112-121.
WANG Fang,LI Chunying,YI Yan,et al.Qualitative Analysis of Metabolites of Aristolochiae Fructus Aqueous Extract in Rats[J].Chinese Journal of Experimental Traditional Medical Formulae,2023,29(13):112-121.
王芳,李春英,易艳等.马兜铃水提物在大鼠体内代谢产物的定性分析[J].中国实验方剂学杂志,2023,29(13):112-121. DOI: 10.13422/j.cnki.syfjx.20230764.
WANG Fang,LI Chunying,YI Yan,et al.Qualitative Analysis of Metabolites of Aristolochiae Fructus Aqueous Extract in Rats[J].Chinese Journal of Experimental Traditional Medical Formulae,2023,29(13):112-121. DOI: 10.13422/j.cnki.syfjx.20230764.
目的
2
基于超高效液相色谱-四极杆-飞行时间质谱法(UPLC-Q-TOF-MS
E
),定性分析马兜铃水提物(AFE)和马兜铃酸Ⅰ(AAⅠ)大鼠体内马兜铃酸类物质(AAs)代谢产物的差异。
方法
2
该实验选取SD大鼠,分别连续灌胃给予AFE(110 g·kg
-1
·d
-1
)和AAⅠ(5 mg·kg
-1
·d
-1
)5 d,收集血清、尿液和粪便。采用ACQUITY UPLC BEH C
18
色谱柱(2.1 mm×100 mm,1.7 μm),流动相甲醇(含0.01%甲酸+5 mmol·L
-1
乙酸铵,A)-水(含0.01%甲酸+5 mmol·L
-1
乙酸铵,B)梯度洗脱(0~1.0 min,10%B;1.0~7.0 min,10%~75%B;7.0~7.2 min,75%~95%B;7.2~10.2 min,95%B;10.2~10.3 min,95%~10%B;10.3~12.0 min,10%B),流速0.3 mL·min
-1
。电喷雾离子源(ESI)正离子模式采集,扫描范围
m
/
z
100~1 200。结合UNIFI 1.9.4.053系统,采用Pathway-MS
E
定性分析鉴定生物样品(血清、尿、粪便)中AAs原型和相关代谢产物的种类,平行比较AFE组和AAⅠ组亚急性毒性实验中大鼠体内代谢产物的异同。
结果
2
与AAⅠ组比较,AFE组血清、尿液与粪便生物样品中分别鉴定出6、10和13个共有代谢产物,以及14、20和30个特有代谢产物。主要AAs成分均遵循去甲基化、硝酸还原和结合等代谢过程。与AAⅠ组的平行比较分析显示,AFE组血清中AAⅠ原型成分和生物样品中多数AAⅠ代谢产物[AAⅠa、马兜铃内酰胺I(ALⅠ)a、7-OHALⅠ及其结合型衍生物等]表达量均明显升高(
P
<
0.05,
P
<
0.01),AFE组粪便中ALⅠ的代谢产物表达量显著低于AAⅠ组(
P
<
0.01),AFE组尿液和粪便中还鉴定出多种AAⅠ组未发现的ALⅠ外排代谢产物。
结论
2
AFE中AAs成分均显示出与AAⅠ成分相近的体内代谢规律,但马兜铃中多种AAs成分共存可能会影响AAⅠ的代谢,通过增加AAⅠ与ALⅠ代谢外排,从而达到减小不良反应作用。
Objective
2
Based on ultra performance liquid chromatography-quadrupole-time-of-flight mass spectrometry(UPLC-Q-TOF-MS
E
) technique, we identified qualitatively the metabolites of aristolochic acid(AAs) in rat in order to analyze the metabolic differences between water extract of Aristolochiae fructus(AFE) and Aristolochic acid Ⅰ(AAⅠ).
Method
2
SD rats were selected and administered AFE(110 g·kg
-1
·d
-1
) or AAⅠ(5 mg·kg
-1
·d
-1
) by oral for 5 days, respectively. Serum, urine and feces were collected after administration. Through sample pretreatment, ACQUITY UPLC BEH C
18
column(2.1 mm×100 mm, 1.7 μm) was used with the mobile phase of 0.01% formic acid methanol(A)-0.01% formic acid water(B, containing 5 mmol·L
-1
ammonium acetate) for gradient elution(0-1 min, 10%B; 1-7 min, 10%-75%B; 7-7.2 min, 75%-95%B; 7.2-10.2 min, 95%B; 10.2-10.3 min, 95%-10%B; 10.3-12 min, 10%B) at a flow rate of 0.3 mL·min
-1
. Positive ion mode of electrospray ionization(ESI
+
) was performed in the scanning range of
m
/
z
100-1 200. In combination with UNIFI 1.9.4.053 system, the Pathway-MS
E
was used to qualitatively analyze and identify the AAs prototype and related metabolites in biological samples(serum, urine and feces), and to compare the similarities and differences of metabolites in rats in the subacute toxicity test between AFE group and AAⅠ group.
Result
2
Compared with AAⅠ group, 6, 10, 13 common metabolites and 14, 20, 30 unique metabolites were identified in biological samples(serum, urine and feces) of AFE group, respectively. Moreover, the main AAs components always followed the metabolic processes of demethylation, nitrate reduction and conjugation. Compared with common metabolites in AAⅠ group, prototype components of AAⅠ in serum and most metabolic derivatives of AAⅠ[AAⅠa, aristolochic lactam Ⅰ(ALⅠ)a, 7-OHALⅠ and its conjugated derivatives] in biological samples were significantly increased in AFE group(
P
<
0.05,
P
<
0.01), except that the metabolic amount of ALⅠ in feces of AFE group was remarkably lowed than that of AAⅠ group(
P
<
0.01). In addition, a variety of special ALⅠ efflux derivatives were also identified in the urine and feces of the AFE group.
Conclusion
2
Although major AAs components in AFE all show similar metabolic rules as AAⅠ components
in vivo
, the coexistence of multiple AAs components in Aristolochiae Fructus may affect the metabolism of AAⅠ, and achieve the attenuating effect by increasing the metabolic effection of AAⅠ and ALⅠ.
国家药典委员会 . 中华人民共和国药典:一部 [M]. 北京 : 中国医药科技出版社 , 2015 : 51 .
国家中医管理局《中华本草》编委会 . 中华本草 [M]. 上海 : 上海科学技术出版社 , 1998 .
侯改灵 , 黄岩杰 , 杨晓青 , 等 . 从临床表现和致病机制再认识马兜铃酸类中药的肾毒性 [J]. 中药药理与临床 , 2019 , 35 ( 2 ): 162 - 166 .
刘静 , 郭日新 , 戴忠 , 等 . 马兜铃酸类成分研究进展 [J]. 世界科学技术—中医药现代化 , 2019 , 21 ( 7 ): 1280 - 1286 .
米士丽 , 施海蔚 , 谭力 , 等 . 9种含马兜铃酸类毒性物质中药材中马兜铃酸类成分的定性与定量分析 [J]. 药学学报 , 2021 , 56 ( 7 ): 1980 - 1987 .
尹浩 , 陈烁吉 , 田小亭 , 等 . 基于HPLC-Q-TOF/MS法分析马兜铃水煎剂化学成分的研究 [J]. 世界科学技术—中医药现代化 . 2019 , 21 ( 7 ): 1319 - 1324 .
贠凯祎 , 徐志超 , 宋经元 . 含马兜铃酸中药及其检测研究进展 [J]. 中国科学:生命科学 , 2019 , 49 ( 3 ): 238 - 249 .
DESAI D C , JACOB J , ALMEIDA A , et al . Isolation,structural elucidation and anti-inflammatory activity of astragalin,(-)hinokinin,aristolactam I and aristolochic acids(Ⅰ & Ⅱ)from Aristolochia indica [J]. Nat Prod Res , 2014 , 28 ( 17 ): 1413 - 1417 .
ZHANG H M , ZHAO X H , SUN Z H , et al . Recognition of the toxicity of aristolochic acid [J]. J Clin Pharm Ther , 2019 , 44 ( 2 ): 157 - 162 .
VANHERWEGHEM J L , DEPIERREUX M , TIELEMANS C , et al . Rapidly progressive interstitial renal fibrosis in young women:Association with slimming regimen including Chinese herbs [J]. Lancet , 1993 , 341 ( 8842 ): 387 - 391 .
NG A W T , SONG L P , HUANG M N , et al . Aristolochic acids and their derivatives are widely implicated in liver cancers in Taiwan and throughout Asia [J]. Sci Transl Med , 2017 , 9 ( 412 ): eaan6446 .
CHEN C J , YANG Y H , LIN M H , et al . Herbal medicine containing aristolochic acid and the risk of hepatocellular carcinoma in patients with hepatitis B virus infection [J]. Int J Cancer , 2018 , 143 ( 7 ): 1578 - 1587 .
陈淑桢 , 董亚萍 , 文文 , 等 . 马兜铃酸肝脏致癌性争议及药物安全性思考 [J]. 第二军医大学学报 , 2021 , 42 ( 1 ): 1 - 7 .
COSYNS J P , GOEBBELS R M , LIBERTON V , et al . Chinese herbs nephropathy-associated slimming regimen induces tumours in the forestomach but no interstitial nephropathy in rats [J]. Arch Toxicol , 1998 , 72 ( 11 ): 738 - 743 .
HAN J , XIAN Z , ZHANG Y , et al . Systematic overview of aristolochic acids:Nephrotoxicity,carcinogenicity,and underlying mechanisms [J]. Front Pharmacol , 2019 , 10 ( 10 ): 648 .
JELAKOVIĆ B , DIKA Ž , ARLT V M , et al . Balkan endemic nephropathy and the causative role of aristolochic acid [J]. Semin Nephrol , 2019 , 39 ( 3 ): 284 - 296 .
KUMAR V , POONAM , PRASAD A K , et al . Naturally occurring aristolactams, aristolochic acids and dioxoaporphines and their biological activities [J]. Nat Prod Rep , 2003 , 20 ( 6 ): 565 - 583 .
姜峰 , 岳丽君 , 朱丹 . 马兜铃酸毒副作用研究概述 [J]. 中国药物评价 , 2021 , 38 ( 5 ): 405 - 408 .
田婧卓 , 刘素彦 , 高月 , 等 . 论含马兜铃酸中药的风险评估、安全用药与科学监管——马兜铃酸种类不同毒性各异,检控马兜铃酸Ⅰ/Ⅱ是关键 [J]. 中国中药杂志 , 2022 , 47 ( 14 ): 3693 - 3700 .
CHAN W , CUI L , XU G , et al . Study of the phase Ⅰand phase Ⅱ metabolism of nephrotoxin aristolochic acid by liquid chromatography/tandem mass spectrometry [J]. Rapid Commun Mass Spectrom , 2006 , 20 ( 11 ): 1755 - 1760 .
DEDI KOVÁ A , BÁRTA F , MARTÍNEK V , et al . In vivo metabolism of aristolochic acid Ⅰ and Ⅱ in rats is influenced by their coexposure [J]. Chem Res Toxicol , 2020 , 33 ( 11 ): 2804 - 2818 .
CHAN W , ZHENG Y , CAI Z . Liquid chromatography-tandem mass spectrometry analysis of the DNA adducts of aristolochic acids [J]. J Am Soc Mass Spectrom , 2007 , 18 ( 4 ): 642 - 650 .
STIBOROVA M , MARTINEK V , FREI E , et al . Enzymes metabolizing aristolochic acid and their contribution to the development of aristolochic acid nephropathy and urothelial cancer [J]. Curr Drug Metab , 2013 , 14 ( 6 ): 695 - 705 .
姬海南 , 李海山 , 宋乃宁 , 等 . 马兜铃酸Ⅰ对小鼠肝脏代谢酶的影响研究 [J]. 中国药物警戒 , 2020 , 17 ( 7 ): 403 - 407,411 .
马虹莹 , 吴敬敬 , 葛广波 , 等 . 马兜铃酸体内代谢及致毒过程研究进展 [J]. 世界科学技术—中医药现代化 , 2019 , 21 ( 2 ): 182 - 189 .
郭忠会 , 郑雪莹 , 梁洁 等 . UPLC-Q-TOF/MS技术结合UNIFI平台快速鉴定鸡骨草化学成分 [J]. 中国药房 , 2022 , 33 ( 23 ): 2852 - 2857,2863 .
HU K , LI C , YU T , et al . Global analysis of qualitative and quantitative metabolism of notoginsenoside R 1 in rat liver-brain-gut axis based on LC-IT-TOF/MS combing mMDF strategy [J]. Phytomedicine , 2022 , 104 : 154261 .
LIU S , XIAN Z , ZHAO Y , et al . Quantitative determination and toxicity evaluation of aristolochic acid analogues in Asarum heterotropoides F. Schmidt(Xixin)and traditional Chinese patent medicines [J]. Front Pharmacol , 2021 , 12 : 761593 .
李春英 , 梁爱华 , 高双荣 , 等 . 大鼠胃癌前病变模型的建立 [J]. 中国中药杂志 , 2012 , 37 ( 1 ): 89 - 93 .
徐晓月 , 江振洲 , 黄鑫 , 等 . 马兜铃酸Ⅰ在大鼠体内的毒代动力学 [J]. 安徽医药 , 2008 , 12 ( 5 ): 398 - 400 .
李倩倩 , 任冠桦 , 叶春华 , 等 . 基于液质联用的人血清代谢组学样品前处理方法研究 [J]. 中国癌症防治杂志 , 2021 , 13 ( 1 ): 75 - 80 .
QIN S , TIAN J , WANG L , et al . Ultra-performance chromatography-electrospray tandem mass spectrometry analysis of bile acid profiles in the enterohepatic circulation following geniposide and acetaminophen-induced liver injury [J]. J Chromatogr A , 2022 , 1680 : 463417 .
林美妤 , 曾琪 , 陈光宇 , 等 . UPLC-Q-TOF-MS技术分析黑参在大鼠血清、尿液及粪便中的化学成分 [J]. 中药新药与临床药理 , 2022 , 33 ( 10 ): 1394 - 1399 .
MENGS U . Acute toxicity of aristolochic acid in rodents [J]. Arch Toxicol . 1987 , 59 ( 5 ): 328 - 331 .
ZHANG J , CHAN C K , HAM Y H , et al . Identifying cysteine, N -acetylcysteine, and glutathione conjugates as novel metabolites of aristolochic acid Ⅰ:emergence of a new detoxification pathway [J]. Chem Res Toxicol , 2020 , 33 ( 6 ): 1374 - 1381 .
STIBOROVA M , ARLT V M , SCHMEISER H H . DNA adducts formed by aristolochic acid are unique biomarkers of exposure and explain the initiation phase of upper urothelial cancer [J]. Int J Mol Sci , 2017 , 18 ( 10 ): 2144 .
VIKTORIYA S S , ATTALURI S . Bioactivation of the human carcinogen aristolochic acid [J]. Carcinogenesis , 2014 , 35 ( 8 ): 1814 - 1822 .
0
浏览量
39
下载量
2
CSCD
关联资源
相关文章
相关作者
相关机构